Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accounts Payables: 2014-2025

Historic Accounts Payables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $10.1 million.

  • Viridian Therapeutics, Inc.\DE's Accounts Payables rose 58.77% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 58.77%. This contributed to the annual value of $2.1 million for FY2024, which is 4.29% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Accounts Payables stood at $10.1 million, which was up 18.14% from $8.5 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Accounts Payables high stood at $14.2 million for Q4 2022, and its period low was $2.1 million during Q4 2024.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Accounts Payables averaged around $5.0 million, with its median value being $3.9 million (2025).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Accounts Payables skyrocketed by 1,508.19% in 2021, and later slumped by 84.27% in 2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Accounts Payables (Quarterly) stood at $2.3 million in 2021, then soared by 511.16% to $14.2 million in 2022, then slumped by 84.27% to $2.2 million in 2023, then dropped by 4.29% to $2.1 million in 2024, then spiked by 58.77% to $10.1 million in 2025.
  • Its Accounts Payables stands at $10.1 million for Q3 2025, versus $8.5 million for Q2 2025 and $3.9 million for Q1 2025.